Literature DB >> 17880432

Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data.

M Richards1, C Altisent, A Batorova, H Chambost, G Dolan, P de Moerloose, M Fraga, C Hermans, A Karafoulidou, R Klamroth, R Lassila, C Rothschild.   

Abstract

A survey of 21 haemophilia doctors, throughout Europe, who care for a total of approximately 5000 patients with bleeding disorders addressing practice and opinions regarding prophylaxis in patients aged 16-24 years and adults aged over 50 years, is presented. The outcome of adolescent patients who reduced or stopped prophylaxis was recorded. Eighteen of 19 respondents would consider modification of established prophylaxis in the adolescent age group, principal considerations being avoidance of risks of further concentrate exposure, predicted poor compliance and treatment costs. The preferred age for modification was 16-20 years, but there was very little consensus on the particular prophylactic regime recommended. Approximately, half of a cohort of 218 patients with severe haemophilia successfully reduced or stopped prophylaxis when they reached adolescence. Only 26 of 92 (28%) of the patient cohort who stopped prophylaxis, required reintroduction of a prophylactic regime and 12 of 59 (20%) of those who reduced the intensity of prophylaxis had to reintroduce a more intensive regime. A majority of respondents would consider starting prophylaxis in those over 50 years. There was no consensus as to indications for this practice or the nature of the prophylaxis protocol. We conclude that there is an absence of consensus on the management of patients with severe haemophilia, as they pass through adolescence and young adulthood, and reach the age of 50. Aggregate outcome data suggest a significant proportion of patients in the 18-22 years age range may be able to reduce or stop prophylaxis. A substantial number of older patients are on prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17880432     DOI: 10.1111/j.1365-2516.2007.01478.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  15 in total

1.  Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.

Authors:  Margaret V Ragni
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

2.  Prophylaxis for adults with haemophilia: towards a personalised approach?

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2012-02-13       Impact factor: 3.443

3.  Prophylaxis for adults with haemophilia: one size does not fit all.

Authors:  Kathelijn Fischer
Journal:  Blood Transfus       Date:  2012-04       Impact factor: 3.443

4.  Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Authors:  Angiola Rocino; Antonio Coppola; Massimo Franchini; Giancarlo Castaman; Cristina Santoro; Ezio Zanon; Elena Santagostino; Massimo Morfini
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

5.  Prophylaxis in haemophilia should be life-long.

Authors:  Mike Makris
Journal:  Blood Transfus       Date:  2012-02-13       Impact factor: 3.443

6.  Intermediate Dose Prophylaxis in Adults with Haemophilia: A Clinical Audit from a Resource Limited Setting.

Authors:  Remya Sudevan; Aswathy Ashok Beenakumari; Rema Ganapathy; Manoj Unni; Geeta Vidyadharan; Neeraj Sidharthan
Journal:  Indian J Hematol Blood Transfus       Date:  2019-09-18       Impact factor: 0.900

7.  The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B.

Authors:  J Michael Soucie; Paul E Monahan; Roshni Kulkarni; Barbara A Konkle; Marshall A Mazepa
Journal:  Blood Adv       Date:  2018-08-28

8.  Pilot randomized, non-inferiority, cross-over trial of once-weekly vs. three times-weekly recombinant factor VIII prophylaxis in adults with severe haemophilia A.

Authors:  M V Ragni; J G Yabes; P F Fogarty; N C Josephson; C M Kessler; A T Neff; L Raffini; K Brummel-Ziedins; C G Moore
Journal:  Haemophilia       Date:  2016-12-11       Impact factor: 4.287

Review 9.  Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.

Authors:  Hans-Christoph Rossbach
Journal:  Vasc Health Risk Manag       Date:  2010-03-03

10.  Barriers and perceived limitations to early treatment of hemophilia.

Authors:  Kapil Saxena
Journal:  J Blood Med       Date:  2013-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.